Idoroenyi Amanam, M.D.

(877) 460-4673
Idoroenyi Amanam, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Leukemia
Research Area
  • Leukemia
  • Stem Cell Transplants
  • Myeloproliferative Neoplasms
Other Languages Spoken
Efik
Ibibio
Academic Appointments
  • Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Leukemia
Research Teams
Hematologic Malignancies Translational Science
Hematology & Hematopoietic Cell Transplantation

I believe in treating all my patients with compassion and utilizing intellectual curiosity to tailor my treatment approaches.

Idoroenyi Amanam, M.D., is a triple-boarded physician with advanced fellowship training utilizing cellular and stem cell therapy to treat malignant conditions. Dr. Amanam obtained his medical degree from Meharry Medical College in Nashville, Tennessee. He completed his training at St. Mary-UCLA Internal Medicine Residency, where he was awarded Intern of the Year, Resident of the Year and Chief Resident distinctions. Following residency, Dr. Amanam completed his hematology and oncology training here at City of Hope®/UCLA-Harbor combined program, serving as chief fellow. He was then awarded the prestigious City of Hope Hematopoietic Cell Transplantation and Cellular Therapy Fellowship, with a concentration on acute leukemias and myeloproliferative neoplasms.

Dr. Amanam is multilingual (English, Ibibio, Efik) and was awarded a U.S. Congressional Award in service — he is motivated to carrying this to the clinic. He firmly believes in serving his patients and enjoys the time spent educating them and their families regarding specifics of their disease.

Dr. Amanam believes he was chosen to enter this field as he had a loved one who struggled with cancer and lived years longer than expected thanks to compassionate care by the doctors and nurses. “That experience always left an impression with me,” he said. “I knew this was the only field for me.”

Dr. Amanam focuses his research on leukemia, stem cell transplants and myeloproliferative neoplasms, when the body produces too many red or white blood cells. “(The) patients are humble,” he explained, “the disease profile is diverse and from a research perspective there is still room for improving outcomes.”

Location

Education & Experience

Board Certifications

  • Basic Life Support Certification
  • Advanced Cardiac Life Support Certification
  • California Medical License
  • Drug Enforcement Agency License
  • Diplomate of the American Board of Internal Medicine
  • 2015, Certification, Internal Medicine
  • 2019, Certification, Medical Oncology
  • 2019, Certification, Hematology

Fellowship

  • 2019–2020, Fellow, Hematopoietic Cell Transplantation and Cellular Therapy, City of Hope, Duarte, CA
  • 2016–2019, Fellow and Chief Fellow, Hematology and Medical Oncology, City of Hope/Harbor-UCLA, Los Angeles, CA

Residency

  • 2015–2016, Chief Resident, Internal Medicine, David Geffen School of Medicine at UCLA, St. Mary-UCLA, Los Angeles, CA
  • 2012–2015, Resident, Internal Medicine, David Geffen School of Medicine at UCLA, St. Mary-UCLA, Los Angeles, CA

Professional Experience

  • 2020–Present, Assistant Clinical Professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Degrees

  • Doctor of Medicine, Meharry Medical College School of Medicine, Nashville, TN

Awards & Memberships

Awards

  • 2019, ASCO Quality Training Program
  • 2018, AACR/ASCO Methods in Clinical Cancer Research Workshop
  • 2017, Clive Davis Research Fellowship Award
  • 2015, Resident of the Year
  • 2015, Conquer Cancer Foundation Resident Travel Award
  • 2014, American College of Physicians
  • 2014, Young Achiever, American College of Physicians
  • 2013, Intern of the Year, Awarded by Department of Medicine with award in Critical Care
  • 2007, Congressional Award, United States Congress, Selected in Category of Voluntary Public Service

Memberships

  • 2016–present, Member, American Society of Hematology
  • 2014–present, Fellow Member, American Society of Clinical Oncology
  • 2011–present, Associate Member, American College of Physicians
  • 2010–present, Member, Physicians for Peace
  • 2004–present, Member, American Medical Association

Publications

  • Salhotra A, Yang D, Al Malki MM, Mokhtari S, Knobler D, Agarwal V, Sandhu K, Park G, Aribi A, Ali H, Aldoss I, Otoukesh S, Arslan S, Ball B, Koller P, Amanam I, Pourhassan H, Blackmon A, Becker P, Pullarkat V, Artz AS, Smith E, Marcucci G, Forman S, Stein A, Nakamura R. Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 Jan;61(1):82-91. doi: 10.1038/s41409-025-02738-4. Epub 2025 Nov 18. PMID: 41254192; PMCID: PMC12819140.
  • Amanam I, Otoukesh S, Pullarkat V, Forman S, Marcucci G, Al Malki M, Ali H. Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications. Blood Rev. 2025 Nov 28:101355. doi: 10.1016/j.blre.2025.101355. Epub ahead of print. PMID: 41344966.
  • Tinajero J, Ngo D, Lee B, Kim H, Ball B, Koller P, Amanam I, Pourhassan H, Ali H, Otoukesh S, Salhotra A, Blackmon A, Sandhu K. FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience. J Oncol Pharm Pract. 2025 Nov 20:10781552251396885. doi: 10.1177/10781552251396885. Epub ahead of print. PMID: 41264473.
  • Harada K, Zhao D, Park M, Chen F, Xu Y, Zhang Y, Zhou Y, Parcutela B, Jewel Y, Munoz A, Amanam I, Nguyen LXT, Chen J, Ghoda L, Forman SJ, Williams JC, Zhang B, Marcucci G. MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia. J Hematol Oncol. 2025 Nov 12;18(1):99. doi: 10.1186/s13045-025-01755-6. PMID: 41225489; PMCID: PMC12613351.
  • Otoukesh S, Amanam I, Yang D, Samuels D, Salhotra A, Artz A, Arslan S, Aldoss I, Sandhu K, Koller P, Aribi A, Curtin P, Stein A, Marcucci G, Al Malki M, Ali H, Rahmanuddin S, Nakamura R, Pullarkat V. Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant. 2025 Dec;60(12):1666-1668. doi: 10.1038/s41409-025-02724-w. Epub 2025 Sep 24. PMID: 40993219.
  • Nguyen T, Markary T, Tsai NC, Tiemann K, Mokhtari S, Samara Y, Pourhassan H, Blackmon A, Arslan S, Otoukesh S, Agarwal V, Amanam I, Ball B, Koller P, Aribi A, Salhotra A, Sandhu K, Pullarkat V, Becker P, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Artz A, Nakamura R, Al Malki MM. Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment. Transplant Cell Ther. 2025 Oct;31(10):824.e1-824.e13. doi: 10.1016/j.jtct.2025.07.001. Epub 2025 Jul 3. PMID: 40617293; PMCID: PMC12416212.
  • Ngo D, Tinajero J, Otoukesh S, Sandhu K, Ali H, Arslan S, Modi B, Amanam I, Nakamura R, Salhotra A. Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease. Expert Opin Investig Drugs. 2025 May;34(5):391-400. doi: 10.1080/13543784.2025.2510667. Epub 2025 May 25. PMID: 40407836.
  • Samuels DT, Yao JM, Samara Y, Yang D, Mokhtari S, Tiemann K, Otoukesh S, Arslan S, Pourhassan H, Wu S, Blackmon A, Agrawal V, Amanam I, Ali H, Salhotra A, Aldoss I, Ball B, Koller P, Aribi A, Sandhu K, Pullarkat V, Artz A, Smith E, Stewart F, Becker P, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide[1]based graft-versus-host-disease prophylaxis. Front Immunol. 2025 Feb 20;16:1543099. doi: 10.3389/fimmu.2025.1543099. PMID: 40051639; PMCID: PMC11882550.
  • Koller PB, Othman T, Yang D, Mokhtari S, Samara Y, Blackmon A, Agrawal V, Pourhassan H, Ball BJ, Amanam I, Arslan S, Otoukesh S, Sandhu KS, Aldoss I, Ali H, Salhotra A, Aribi A, Artz A, Becker PS, Pullarkat V, Stewart FM, Smith EP, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect. Bone Marrow Transplant. 2025 May;60(5):625-631. doi: 1038/s41409-025-02523-3. Epub 2025 Feb 27. PMID: 40016513; PMCID: PMC12061766.
  • Modi B, Ngo D, Chen J, Yang D, Shan H, Sandhu K, Rashid N, Amanam I, Otoukesh S, Nakamura R, Ali H, Salhotra A. Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience. Bone Marrow Transplant. 2025 Apr;60(4):555-557. doi: 10.1038/s41409-024-02498-7. Epub 2025 Feb 4. PMID: 39905130.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Show respect for what you say
5.0
Spend enough time with you
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Rate provider 0-10
03/29/26
Dr. Amanan is very thorough and personable. He is courteous and pleasant and gives the patient his full attention. - Verified patient
03/25/26
Good - Verified patient
03/25/26
Very good - Verified patient
03/23/26
The doctor was his usual self, attentive and listening. - Verified patient
03/23/26
[...] The doctor and team (RNs) were excellent [...] - Verified patient